NovaBridge Biosciences
NBPNext catalyst
Phase 2 Results - givastomig
Get an email about NBP's next catalysts
Track NovaBridge Biosciences (NBP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Phase 2 Results - givastomig
For HER2-negative, first-line metastatic gastric cancer. NovaBridge Biosciences initiated a global Phase 2 study of givastomig, a CLDN18.2-directed bispecific antibody, combined with nivolumab and chemotherapy in first-line metastatic gastric cancer patients. Top-line results are expected in 2027.
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is NovaBridge Biosciences's next FDA catalyst?→
NovaBridge Biosciences's (NBP) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NBP biotech catalysts?→
Add NBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NovaBridge Biosciences's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.